Lung Cancer Diagnostics Market is estimated to increase at a growth rate of 9.3% CAGR over the forecast period from 2024 to 2030.
The global Lung Cancer Diagnostics Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Instruments, Consumables & Accessories), By Test (Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Others), By End-user (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), By Distribution Channel (Direct Tender, Retail Sales).
An introduction to Lung Cancer Diagnostics Market in 2024
At the forefront of oncology diagnostics, the Lung Cancer Diagnostics market encompasses a diverse array of imaging modalities, molecular assays, and biomarker tests aimed at accurate disease detection, staging, and treatment stratification. With a shifting paradigm towards precision medicine, diagnostic companies are developing innovative technologies to identify genetic mutations, protein markers, and imaging characteristics associated with lung cancer subtypes. The market is propelled by the global burden of lung cancer, the imperative for early detection strategies, and the emergence of targeted therapies and immunotherapies revolutionizing treatment paradigms.
Lung Cancer Diagnostics Market Trend: Advancements in Precision Medicine and Molecular Diagnostics
A significant trend in the Lung Cancer Diagnostics market is the rapid advancements in precision medicine and molecular diagnostics for the detection and characterization of lung cancer. With a deeper understanding of the molecular mechanisms driving lung cancer development and progression, there is a shift towards personalized treatment approaches that target specific genetic alterations and biomarkers. Molecular diagnostic techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and immunohistochemistry (IHC) are increasingly used to identify actionable mutations and guide treatment decisions, leading to more effective and tailored therapies for lung cancer patients.
Lung Cancer Diagnostics Market Driver: Increasing Incidence of Lung Cancer Worldwide
A key driver for the Lung Cancer Diagnostics market is the increasing incidence of lung cancer globally, driven by factors such as smoking prevalence, environmental exposures, and aging populations. Lung cancer remains one of the most common and deadliest cancers worldwide, with a high mortality rate and significant public health burden. Early detection and accurate diagnosis are crucial for improving patient outcomes and survival rates, fueling the demand for advanced diagnostic technologies and screening programs for lung cancer detection and staging.
Lung Cancer Diagnostics Market Opportunity: Expansion into Liquid Biopsy and Non-invasive Diagnostic Modalities
An opportunity within the Lung Cancer Diagnostics market lies in the expansion into liquid biopsy and non-invasive diagnostic modalities for lung cancer detection and monitoring. Liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis and circulating tumor cells (CTCs) enumeration, offer minimally invasive alternatives to traditional tissue biopsy for assessing tumor biomarkers and treatment response in lung cancer patients. Additionally, non-invasive imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) play crucial roles in lung cancer staging and surveillance. By investing in the development and commercialization of liquid biopsy assays and non-invasive imaging technologies, stakeholders in the Lung Cancer Diagnostics market can capitalize on the growing demand for less invasive and more accessible diagnostic approaches, ultimately improving patient care and outcomes.
Lung Cancer Diagnostics Market Market Segmentation
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Lung Cancer Diagnostics Market Companies
20/20 Gene Systems
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
Reasons to Buy the Lung Cancer Diagnostics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Lung Cancer Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Lung Cancer Diagnostics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Lung Cancer Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Lung Cancer Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Lung Cancer Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Lung Cancer Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Lung Cancer Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Lung Cancer Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Lung Cancer Diagnostics Industry
4.2 Key Market Trends in Lung Cancer Diagnostics Industry
4.3 Potential Opportunities in Lung Cancer Diagnostics Industry
4.4 Key Challenges in Lung Cancer Diagnostics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Lung Cancer Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Lung Cancer Diagnostics Market Outlook by Segments
7.1 Lung Cancer Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
8 North America Lung Cancer Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Lung Cancer Diagnostics Markets in 2024
8.2 North America Lung Cancer Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Lung Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
9 Europe Lung Cancer Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Lung Cancer Diagnostics Markets in 2024
9.2 Europe Lung Cancer Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Lung Cancer Diagnostics Market Size Outlook by Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
10 Asia Pacific Lung Cancer Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Lung Cancer Diagnostics Markets in 2024
10.2 Asia Pacific Lung Cancer Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Lung Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
11 South America Lung Cancer Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Lung Cancer Diagnostics Markets in 2024
11.2 South America Lung Cancer Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Lung Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
12 Middle East and Africa Lung Cancer Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Lung Cancer Diagnostics Markets in 2024
12.2 Middle East and Africa Lung Cancer Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Lung Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
20/20 Gene Systems
Abbott
Amoy Diagnostics Co. Ltd
Biocartis
Biodesix
Bio-Rad Laboratories Inc
Boditech Med Inc
Danaher
DiaSorin S.p.A.
Exact Sciences UK Ltd
F. Hoffmann-La Roche Ltd.
Guardant Health Inc
Inivata Ltd.
LalPathLabs.com
LungLife AI Inc
MedGenome
Myriad Genetics Inc
Nanoentek
NanoString
NeoGenomics Laboratories
Oncocyte Corp
PerkinElmer Inc
PlexBio
QIAGEN
Quest Diagnostics Inc
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc
Vela Diagnostics
Veracyte Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Instruments
Consumables & Accessories
By Test
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others
By End-User
Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Distribution Channel
Direct Tender
Retail Sales
